Clinical Trial

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study is designed to characterize the PK of nalmefene following IV bolus and IM injections using nalmefene 0.5 mg (0.94% MgCl2) and IV bolus of 0.5 mg nalmefene hydrochloride injection in healthy subjects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-15; most recent amendment 2026-06-03.
Trial Details
NCT Number NCT07543276
Lead Sponsor Knoa Pharma LLC
Collaborators: Purdue Pharma LP
Conditions Opioid Overdose
Enrollment 13 participants
Start Date 2026-02-06
Primary Completion 2026-04-03 (estimated)
Study Completion 2026-04-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-05